Carvykti demonstrated a 59 percent reduction in disease progression or death in its Phase 3 study. How does this efficacy benchmark influence the current therapeutic landscape for multiple myeloma?

Considering the approval for Carvykti post at least one prior therapy line, how critical is the timing of intervention in the management of relapsed and refractory multiple myeloma?

How does Carvykti compare to traditional treatments like pomalidomide, bortezomib, and dexamethasone or combinations with daratumumab in terms of patient outcomes and safety profiles?

From your experience, how has the introduction of CAR T-cell therapies, such as Carvykti, changed the approach to patient management in multiple myeloma?

Given the serious potential adverse effects like CRS and neurotoxicities associated with Carvykti, what are the recommended strategies for managing these risks in clinical settings?

With Johnson & Johnson’s efforts to scale up manufacturing, how do you foresee the impact of increased availability of Carvykti on its adoption in clinical practice?

What long-term impacts might Carvykti have on survival rates and quality of life for patients with multiple myeloma?

What are the next steps in research for Carvykti, and what potential studies are needed to further ascertain its place in therapy, especially in earlier lines of treatment?